Chen, Kai-LungKai-LungChenCHIA-CHI LINYUNG-TSU CHOYang, Che-WenChe-WenYangYI-SHUAN SHEENTsai, Hsiao-EnHsiao-EnTsaiCHIA-YU CHU2019-12-042019-12-042016-032168-6068https://www.scopus.com/inward/record.uri?eid=2-s2.0-84962143979&doi=10.1001%2fjamadermatol.2015.4448&partnerID=40&md5=0c0665512d8542f02fdb679fba5398d2https://scholars.lib.ntu.edu.tw/handle/123456789/434698en[SDGs]SDG3afatinib; erlotinib; gefitinib; afatinib; antineoplastic agent; erlotinib; gefitinib; quinazoline derivative; acne; adverse outcome; controlled study; human; incidence; Letter; major clinical study; non small cell lung cancer; outcome assessment; paronychia; priority journal; pruritus; retrospective study; skin toxicity; xerosis; Acneiform Eruptions; Carcinoma, Non-Small-Cell Lung; chemically induced; cohort analysis; comparative study; compassionate use; cross-sectional study; Drug Eruptions; ichthyosis; Lung Neoplasms; paronychia; pruritus; Acneiform Eruptions; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studiesletter10.1001/jamadermatol.2015.4448266496812-s2.0-84962143979